Please assess the completion status of the following clinical trial:

Trial Title: A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Boys and Girls Age 9 to 15:~* Participant has not had sexual intercourse prior to the study and does not plan to become sexually active during the study period Day 1 to Month 7~Women Age 16 to 26:~* Participant has never had Pap testing or has had only normal results~* Participant has had 0 to 4 sexual partners at the time of enrollment~Exclusion Criteria:~Boys and Girls Age 9 to 15:~* History of allergic reaction that required medical intervention~* Currently enrolled in any other clinical study~* Participant is pregnant~* Participant is immunocompromised or has taken immunosuppressants in the last year~* Participant has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial~* Participant has a history of positive test for HPV~Women Age 16 to 26:~* History of allergic reaction that required medical intervention~* Currently enrolled in any other clinical study~* Participant is pregnant~* Participant is immunocompromised or has taken immunosuppressants in the last year~* Participant has received a marketed HPV vaccine or participated in an HPV vaccine clinical trial~* Participant has a history of positive test for HPV~* Participant has a history of abnormal cervical biopsy result~* Participant has a history of external genital lesions

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- 9- to 15-Year-Old Females (Lot 1) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
- 9- to 15-Year-Old Females (Lot 2) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
- 9- to 15-Year-Old Females (Lot 3) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
- 9- to 15-Year-Old Males (Lot 1) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
- 16- to 26-Year-Old Females (Lot 1) (Type: EXPERIMENTAL): 9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).